Fusion glycoprotein

Fusion glycoprotein

Fusion glycoprotein Overview

Molecule Name
Respiratory syncytial virus F protein
Synonyms
Fusion glycoprotein, F protein, F, Nipah virus, Hendra virus
Drug Development Progress
Drugs in Clinical Trials5
Approved Drugs3
Highest Development StageApproved
Target Synonym
Protein F,F,Fusion glycoprotein F0
Background
Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.

Fusion glycoprotein Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
CPI-RSV-F VaccineBLB-201Phase 2 ClinicalBlue Lake Biotechnology Inc
Respiratory Syncytial Virus Infections
Details
RSV vaccine (Vaxart)Phase 1 ClinicalVaxart Biosciences Inc
Respiratory Syncytial Virus Infections
Details
GR-2102GR2102; GR-2102Phase 1 ClinicalChongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd
Respiratory Syncytial Virus Infections
Details
Palivizumab biosimilar (mAbxience)MB-05Phase 1 ClinicalMabxience Sa
Details
RSM-01Phase 1 ClinicalBill & Melinda Gates Medical Research Institute
Respiratory Syncytial Virus Infections
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
NirsevimabAnti-RSV-mAb-D25; SP-0232; MEDI-8897; Anti-RSV MAb-YTEApprovedAimm Therapeutics, MedImmune Inc, SanofiBeyfortus, 乐唯初EURespiratory Syncytial Virus InfectionsSanofi Winthrop Industrie SA2022-10-31
Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections
Details
PalivizumabABT-315; MEDI-493ApprovedAbbvie Inc, Medimmune LlcSynagisUnited StatesRespiratory Syncytial Virus InfectionsSwedish Orphan Biovitrum Ab (Publ)1998-06-19
Bronchiolitis; Bronchopulmonary Dysplasia; Heart Defects, Congenital; Infant, Premature, Diseases; Premature Birth; Respiratory Syncytial Virus Infections
Details
Respiratory syncytial virus immune globulinRSV-IGIVApprovedMedimmuneRespiGamUnited StatesRespiratory Syncytial Virus Infectionsnull1996-01-01
Respiratory Syncytial Virus Infections
Details